Projet MEDICIS-PROMED (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Information Science and Engineering
Statut du projet : CLOSED

Pure accelerated radioisotope beams have been used for 50 years in fundamental physics R&D, e.g. for nuclear structure studies (pear shaped exotic nuclei, Nature 2013); CERN-ISOLDE plays a central role in developing accelerator technologies and fostering collaborative approaches to advance this field of isotope mass separation online. Our most recent contribution was the use of nanomaterial targets for more intense and reliable beam production, and laser ion sources for their purification (discovery of yet unknown 233Francium). Radioisotopes are widely used for functional imaging in medicine, based on 99mTechnetium or on 18Fluorine. This field is expected to rapidly expand, when coupling imaging with new cancer treatments, with isotopes emitting different type of radioactivity, e.g. alpha particles. This is shown with the recently introduced 223Radium chloride (Xofigo®) used as a treatment drug in advanced bone cancers. However, either shortage in the supply of 99mTechnetium or lack of access to new radioisotope with adequate properties is a severe treat to develop personalized treatment that combine functional imaging and therapy. Ovarian cancers have poor prognosis, are the second most frequent cancer for women and one of the deadliest. They are difficult to treat, because of possible presence of metastasis, and because this region is difficult to irradiate without collateral damages. MEDICIS-PROMED will train a new generation of scientists to develop systems for personalized Medicine combining functional imaging and treatments based on radioactive ion beam mass-separation. This will be done across a coherent intersectorial multidisciplinary network with world-leading scientists in their field. Subsystems for the development of new radiopharmaceuticals, of isotope mass separators at medical cyclotrons, and of mass separated 11Carbon for PET-aided hadron therapy will be specifically developed to treat the ovarian cancer.

Mots clés : isotope mass separation, targeted radiotherapy, theranostic isotope pairs, hadron therapy with pet carbon ions, pet imaging, radiopharmaceuticals, ovarian cancer

Participants :
- Johannes Gutenberg University Mainz (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- Board of the Swiss Federal Institutes of Technology (Suisse) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- European Organization for Nuclear Research (Suisse) — Coordinator, beneficiary, Recherche, subvention : 795680.28 €
- Groupement interet public arronax (France) — Partner, organization partner, Recherche, subvention : 0.0 €
- KU Leuven (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 250560.0 €
- University Hospital of Geneva (Suisse) — Partner, organization partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €
- University of Lisbon (Portugal) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 476712.72 €
- National Centre of Oncological Hadrontherapy (Italie) — Partner, beneficiary, Recherche, subvention : 258061.32 €
- Ebg medaustron gmbh (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut Max von Laue – Paul Langevin (France) — Partner, organization partner, Recherche, subvention : 0.0 €
- Advanced accelerator applications (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 262875.6 €
- Lemer pax (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 262875.6 €
- University of Manchester (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- Isis innovation ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University Hospital of Lausanne (Suisse) — Partner, organization partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €